20.06.2012 - Institutional investors doubt that treatments for Alzheimer's disease being developed by Pfizer and Eli Lilly will achieve the main goals of their ongoing late-stage trials, but...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)